Inovio Pharmaceuticals (NASDAQ:INO) Given "Neutral" Rating at HC Wainwright

Key Points

• HC Wainwright has reiterated a "neutral" rating for Inovio Pharmaceuticals (INO) with a price target of $3.00, indicating a potential upside of 76.47% from the current stock price.
• Multiple analysts have varying views on INO, with ratings ranging from "hold" to "overweight", and an average target price of $8.80.
• Inovio recently reported an EPS of ($0.61), surpassing consensus estimates, and analysts expect the company to post -4.23 earnings per share for the current year.

HC Wainwright reissued their neutral rating on shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) in a research report released on Thursday,Benzinga reports. They currently have a $3.00 price objective on the biopharmaceutical company's stock.

INO has been the subject of several other research reports. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, June 27th. Royal Bank Of Canada reissued a "sector perform" rating and set a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Oppenheimer cut their price objective on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a report on Wednesday, May 14th. Finally, Piper Sandler began coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $5.00 target price for the company. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $8.80.

Inovio Pharmaceuticals Stock Down 0.3%

Inovio Pharmaceuticals stock traded down $0.0050 during midday trading on Thursday, reaching $1.8950. The stock had a trading volume of 907,680 shares, compared to its average volume of 1,213,707. Inovio Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $7.90. The firm's 50-day moving average price is $1.67 and its 200 day moving average price is $1.83. The firm has a market capitalization of $69.49 million, a PE ratio of -0.73 and a beta of 1.38.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.02. Equities research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nomura Holdings Inc. purchased a new stake in Inovio Pharmaceuticals in the first quarter worth $28,000. Alpine Global Management LLC purchased a new stake in Inovio Pharmaceuticals in the fourth quarter worth $31,000. Catalyst Funds Management Pty Ltd purchased a new stake in Inovio Pharmaceuticals in the second quarter worth $35,000. Freedom Investment Management Inc. purchased a new stake in Inovio Pharmaceuticals in the first quarter worth $31,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 5,894 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.